EC Number |
Natural Substrates |
---|
1.1.1.141 | (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ |
- |
1.1.1.141 | (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ |
catabolism of (15S)-PGE2 |
1.1.1.141 | (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ |
first step in prostaglandin catabolism |
1.1.1.141 | (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ |
first step in prostaglnadin catabolism |
1.1.1.141 | (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ |
i.e. 15-hydroxyprostaglandin or (15S)-PGE2 |
1.1.1.141 | (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ |
key step in prostaglandin catabolism, enzyme activation leads to reduced cell proliferation, the enzyme is an antagonist of ibuprofen |
1.1.1.141 | (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ |
key step in prostaglandin inactivation |
1.1.1.141 | (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ |
PGE2 degradation |
1.1.1.141 | (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ |
prostaglandin E2, PGE2, a proinflammatory bioactive lipid, promotes cancer progression by modulating proliferation, apoptosis, and angiogenesis, PGE2 is a downstream product cyclooxygenase and is biochemically inactivated by the enzyme |
1.1.1.141 | (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate + NAD+ |
reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells, overview |